UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced the early termination of the pivotal Phase III PIVOT-PO trial (NCT06059846) for tebipenem HBr, an investigational oral treatment for complicated urinary tract infections (cUTIs), including pyelonephritis. The decision follows a recommendation by the Independent Data Monitoring Committee (IDMC) after an interim analysis demonstrated superior efficacy in 1,690 enrolled patients.
Trial Success and Regulatory Plans
The study achieved its primary endpoint of non-inferiority of tebipenem HBr compared to intravenous imipenem-cilastatin in hospitalized adult patients with cUTI. The results showed comparable overall response rates, combining clinical cure and microbiological eradication, at the test-of-cure visit. GSK plans to submit data to U.S. regulators in the second half of 2025.
Potential Market Impact
If approved, tebipenem HBr would mark a significant advancement as the first oral carbapenem antibiotic for cUTI in the U.S. This milestone highlights GSK’s commitment to addressing unmet needs in infectious disease treatment and could offer patients a more convenient and effective therapeutic option.-Fineline Info & Tech
